Arcutis reports 70% revenue increase for Zoryve in third-quarter 2023 results

Key takeaways:

• Zoryve (roflumilast cream 0.3%) saw a 70% increase in revenue from the second quarter of 2023.
• Arcutis achieved total revenues of $38.1 million.

Arcutis reported its financial results for the third quarter of 2023, which included a total revenue of $38.1 million and a 70% increase in Zoryve revenue, according to a company press release.

Upon the closing of its third quarter, Arcutis announced that Zoryve, the company’s roflumilast 0.3% cream product for the treatment of plaque psoriasis, produced $8.1 million in net product revenue, a 70% increase from the second quarter of the year.

“We are very pleased with the performance this quarter, and believe we are well positioned for continued strong net product revenue growth in the fourth quarter and to accelerate that momentum into 2024,” Frank Watanabe, president and CEO of Arcutis, said in the release. “We are on the cusp of a very significant expansion of the topical roflumilast opportunity during 2024 with the potential approvals and subsequent launches of topical roflumilast for seborrheic dermatitis and atopic dermatitis as well as expected further expansion of payer coverage.”

The company also provided business updates, such as receiving FDA approval for the expanded indication of Zoryve in plaque psoriasis for patients aged as young as 6 years, according to the press release.

More than 110,000 prescriptions for Zoryve have been filled by nearly 9,000 prescribers since the product’s 2022 launch, the company reports.

Arcutis also submitted a supplemental new drug application to the FDA for roflumilast cream 0.15% and announced positive long-term results from the INTEGUMENT-OLE trial.